Randomised Clinical Trial for New Treatment Modalities for Cutaneous Leishmaniasis Caused by Leishmania Tropica, in Pakistan

NCT ID: NCT04268524

Last Updated: 2025-05-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 832 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-07
• Study Completion Date: 2026-01-31

Brief Summary

randomised control clinical trial to evaluate miltefosine, thermotherapy and the combination miltefosine-thermotherapy are effective, safe and tolerable alternative treatment options to treat cutaneous leishmaniasis caused by L. tropica, in Pakistan compared to the standard of care.

Detailed Description

Until now, there is no well-established evidence based option to treat CL caused by the Leishmania tropica, besides antimonial injections. Alternative treatment options are not available in Pakistan, or there is limited evidence of the effectivity.

Effectiveness of thermotherapy in L. tropica is studied in only three studies in OWCL with a variable cure rate (54.1% - 98%). But it could be an attractive option, because only one treatment session is required and studies report less scarring tissue. Another promising treatment option is oral miltefosine. There is considerable evidence in the literature of the efficacy of miltefosine in treatment of CL caused by L. major, however no studies have been conducted to evaluate the efficacy in CL caused by L. tropica species. This oral treatment could have major benefits for CL patients as it can be provided in peripheral health facilities and to patients who have contraindications to antimony treatment (elderly, and patients with cardiac or renal disease, or diabetes). A combination of thermotherapy and miltefosine, the advantages offered by this combination are that a) the use of a topical plus a systemic treatment would hypothetically have an additive effect of two treatments with different modes of action. For the reason that systemic treatment could eliminate those circulating or remaining parasites located in the periphery of the lesion that topical treatment fails to remove, which might be the cause of a relapse, b) it may reduce the necessary length of treatment with miltefosine. For these above reasons, in a prospective trial we aim to evaluate the effectiveness and safety of thermotherapy, miltefosine and the combination of thermotherapy and miltefosine in CL caused by L. tropica, with the objective to find a treatment with an efficacy which is non-inferior to the standard of care with antimony injections.

Conditions

Old World Cutaneous Leishmaniasis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

monotherapy miltefosine

Miltefosine capsules (Impavido®) 2.5 mg/kg daily PO for 28 days \<30 kg BW allometric miltefosine dose based on fat-free mass. (approx. 2.5 mg/kg); \>30 - ≤44kg BW: 100 mg/day BID; ≥45kg BW 150mg TDS

Group Type: EXPERIMENTAL

drug: miltefosine with thermotherapy

Intervention Type: COMBINATION_PRODUCT

see previous

Thermotherapy

Thermotherapy (ThermoMed 1.8 ®) 50°C for 30 seconds, 1 session

Group Type: EXPERIMENTAL

drug: miltefosine with thermotherapy

Intervention Type: COMBINATION_PRODUCT

see previous

Combination miltefosine and thermotherapy

Miltefosine capsules 2.5 mg/kg daily PO for 21days, and thermotherapy 50°C for 30 seconds, one session on day 1 of the miltefosine.

Group Type: EXPERIMENTAL

drug: miltefosine with thermotherapy

Intervention Type: COMBINATION_PRODUCT

see previous

° Meglumine antimoniate (Glucantime®) intralesional

Meglumine antimoniate (Glucantime®) intralesional injections 0.5-3ml, 8 sessions, bi-weekly

Group Type: ACTIVE_COMPARATOR

No interventions assigned to this group

Interventions

drug: miltefosine with thermotherapy

see previous

Intervention Type: COMBINATION_PRODUCT

Other Intervention Names

device ThermoMed 1.8

Eligibility Criteria

Inclusion Criteria

• Male and female patients with clinical and laboratory confirmed CL, and who can be treated with localised intralesional antimonial injections and/or thermotherapy:
• lesion size ≥0.5 cm and ≤4 cm
• not located on the ear, nose, near to the eye or mucosal membranes, on joints, or on a location that in the opinion of the principle investigator (PI) is difficult to apply thermotherapy (TT) or intralesional (IL) injections
• patient with ≤4 lesions
• duration of lesions less than five months by patient history
• Patients who have signed the informed consent form.

Exclusion Criteria

• Pregnant women and breast feeding women
• Non-pregnant women in reproductive age refusing effective (injectable) contraception for a period of five months
• Patients <10years old
• Patients who cannot be treated with localised IL antimonial injections or TT (patients with more than 4 lesions, lesions >4cm in diameter, or located on joints, lips, nose, ears or near eyes)
• History of clinically significant medical problems or treatment that might interact with the study treatment and interact with wound healing, such as diabetes, vascular diseases and any immunocompromising condition
• Within eight weeks of trial D1 received treatment for leishmaniasis with any medication
• History of known or suspected hypersensitivity of idiosyncratic reactions to trial medication or excipients
• Has laboratory values at screening: serum creatinine above normal level; ALT 3 times above normal range
• Patient who is not willing to attend the trial visits, or is not able to comply with follow-up visits up to three months.
• Known history of drug addiction and/or alcohol abuse

• Minimum Eligible Age: 10 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medecins Sans Frontieres, Netherlands

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Koert Ritmeijer

Role: STUDY_DIRECTOR

Medecins Sans Frontieres, Netherlands

Locations

Kuchlak Primary Health Care Centre (MCH)

Kuchlagh, Balochistan, Pakistan

Site Status: RECRUITING

Shaheed Mohtarma Benazir Bhutto General Hospital

Quetta, Balochistan, Pakistan

Site Status: RECRUITING

Countries

Pakistan

Central Contacts

Suzette Sabine Kämink

Role: CONTACT

s.s.kamink@gmail.com

+31643690015

Koert Ritmeijer

Role: CONTACT

koert.ritmeijer@oca.msf.org

+31 6 24453143

Facility Contacts

Suzette Sabine Kamink

Role: primary

s.s.kamink@gmail.com

+31643690015

Suzette Sabine Kamink

Role: primary

s.s.kamink@gmail.com

+31643690015

Other Identifiers

CL_RCT_MF_vs_TT_2020

Identifier Type: -

Identifier Source: org_study_id